Breaking: Trump Signs Executive Order to Accelerate Psychedelic Research – But Critics Say Racial Disparities Threaten Access
WASHINGTON – President Donald Trump has signed an executive order to fast-track clinical research and treatment using psychedelic drugs, flanked by podcaster Joe Rogan and a group of Make America Healthy Again (MAHA) loyalists. But mental health experts and civil rights advocates warn that the so-called “psychedelic revolution” is leaving behind people of color.
“The current boom in psychedelic therapy is largely white and wealthy,” said Dr. Monnica Williams, a clinical psychologist and leading researcher on race and psychedelics at the University of Ottawa. “If we don’t deliberately include Black, Indigenous, and Latino communities now, these treatments will widen already severe mental health disparities.”
Background: From Ancient Use to Whitewashed Revival
Use of naturally occurring and synthetic hallucinogens traces back to Neanderthals. Yet these substances have long been stigmatized in mainstream medicine as “club drugs” with no clinical value. Recent studies on psilocybin and MDMA for depression and PTSD have sparked a renaissance, but the benefits remain concentrated among affluent, white patients.
Historical drug war policies disproportionately incarcerated people of color for possession of the very substances now being celebrated as therapeutic. “The same communities that were criminalized for using these plants are now being priced out of the clinics,” said Dr. Carl Hart, a neuroscientist at Columbia University who studies drug policy and race.
What This Means: A Two-Tiered System for Mental Health
Without targeted outreach and affordability measures, the executive order could create a two-tier system: high-cost ketamine clinics for the wealthy and continued criminalization for low-income communities of color. The order does not address cost, insurance coverage, or equity in clinical trials.
“An executive order that accelerates access without addressing cost and inclusion is dangerous,” said Ms. Jasmine Black, founder of the nonprofit Psychedelic Equity Project. “We need community-based research, not just more private equity in fancy clinics.”
Key Reactions
- Dr. Monnica Williams: “We need mandated diversity in clinical trials and sliding-scale payment models.”
- Dr. Carl Hart: “This policy continues to prioritize profit over justice.”
- White House spokesperson (on background): “The order removes bureaucratic barriers for all Americans, regardless of race.”
What Happens Next
Federal agencies have 90 days to propose rules for expanded research. Advocacy groups are planning a lobbying push to include equity requirements. Meanwhile, industry insiders predict a surge in private investment—but not in underserved neighborhoods.
This story is developing. Check back for updates.